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DNA topoisomerase IIα interacts with CAD nuclease and is
involved in chromatin condensation during apoptotic execution
Françoise Durrieu*†, Kumiko Samejima*†, John M. Fortune‡,
Stefanie Kandels-Lewis*, Neil Osheroff‡ and William C. Earnshaw*
Apoptotic execution is characterized by dramatic
changes in nuclear structure accompanied by cleavage
of nuclear proteins by caspases (reviewed in [1]).
Cell-free extracts have proved useful for the
identification and functional characterization of
activities involved in apoptotic execution [2–4] and for
the identification of proteins cleaved by caspases [5].
More recent studies have suggested that nuclear
disassembly is driven largely by factors activated
downstream of caspases [6]. One such factor, the
caspase-activated DNase, CAD/CPAN/DFF40 [4,7,8]
(CAD) can induce apoptotic chromatin condensation in
isolated HeLa cell nuclei in the absence of other
cytosolic factors [6,8]. As chromatin condensation occurs
even when CAD activity is inhibited, however, CAD
cannot be the sole morphogenetic factor triggered by
caspases [6]. Here we show that DNA topoisomerase IIα
(Topo IIα), which is essential for both condensation and
segregation of daughter chromosomes in mitosis [9],
also functions during apoptotic execution. Simultaneous
inhibition of Topo IIα and caspases completely abolishes
apoptotic chromatin condensation. In addition, we show
that CAD binds to Topo IIα, and that their association
enhances the decatenation activity of Topo IIα in vitro.
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Results and discussion
HeLa nuclei incubated in E/X extracts underwent chro-
matin condensation in two stages: condensation against
the nuclear rim was followed by the formation of discrete
apoptotic bodies (Figure 1b). The rim-condensation
also occurred when caspase activity was inhibited with
the peptide–fluoromethylketone inhibitor DEVD–fmk
(Figure 1c) [6]. A similar phenotype was observed when
nuclei were preincubated with the highly specific Topo II
inhibitors ICRF-159, ICRF-187 or etoposide (VP16) for
30 minutes before addition of E/X extracts (Figure 1d–f).
Simultaneous inhibition of caspase and Topo II activity
completely abolished apoptotic chromatin condensation
(Figure 1d′–f′). This was not simply a kinetic effect, as
nuclei retained this normal appearance for at least 6 hours
at 37°C (data not shown). This inhibition of apoptotic
chromatin condensation was unlikely to arise from global
changes in the accessibility of chromatin to condensation
factors, as simultaneous inhibition of caspases and
Topo IIα had no effect on the ability of CAD nuclease to
cleave nuclear DNA into an oligonucleosomal ladder
(Figure 2e). These experiments provide the first evi-
dence that Topo IIα has a role in chromatin condensation
during apoptosis.
The abolition of apoptotic chromatin condensation follow-
ing simultaneous inhibition of Topo IIα and caspases was
seen with three different Topo II inhibitors, suggesting
that the effect is due to the action of the drugs on
Topo IIα. In a further control, apoptotic chromatin con-
densation was restored when highly purified human
Topo IIα [10] (Figure 2d) was added to nuclei in E/X
extract in the presence of Topo II and caspase inhibitors
(Figure 1d′′–f′′). This rescue was abrogated when the puri-
fied Topo IIα was pretreated with monospecific anti-Topo
IIα antibodies (Figure 2b, and data not shown). Topo IIα
alone had no effect on the morphology of nuclei in buffer
after 2 hours (Figure 2a). Finally, simultaneous inhibition
of Topo I and caspases had no effect on chromatin conden-
sation induced by E/X extracts (Figure 2c). These controls
strongly support the conclusion that both Topo IIα and
caspases act in pathways that promote apoptotic chromatin
condensation. The rescue by purified Topo IIα in the
presence of inhibitors raises the possibility that Topo IIα
could be functioning in a non-enzymatic role, either as a
structural or targeting factor, as has been proposed for its
role in mitotic chromosome condensation [11].
Simultaneous inhibition of caspases and CAD (by addition
of the CAD-inhibitory chaperone ICAD-L) also blocked
chromatin condensation in E/X extracts (Figure 1h). This
confirmed our previous results suggesting that CAD and
caspases act in parallel pathways of apoptotic chromatin
condensation [6]. Surprisingly, inhibition of chromatin
condensation could be reversed upon addition of purified
human Topo IIα (Figure 1i), suggesting that Topo IIα
acts downstream of CAD or promotes condensation in a
pathway parallel to the CAD pathway. It was also possible,
however, that the added Topo IIα might interfere with
the interaction between CAD and the exogenous ICAD
added in these reactions as a CAD inhibitor. 
Physical and functional interactions between Topo IIα
and CAD were readily detected both in vitro and in cell
extracts. Purified Topo IIα bound quantitatively to GST–
CAD on glutathione–sepharose, but not to GST alone,
GST–ICAD-L, GST–BubR1, GST–AIRK2, or GST–β
tubulin (data not shown), or sepharose alone (Figure 3a).
As a control, purified poly(ADP-ribose) polymerase
(PARP) added to the mix did not bind to any protein
(Figure 3a). Similar Topo IIα binding was also observed
with Intein–CAD (data not shown).
To confirm that Topo IIα can bind CAD in cell extracts,
we made stable sublines of chicken MSB-1 cells express-
ing green fluorescent protein (GFP) fused to histidine
(His) and haemagglutinin (HA) tags (His–HA–GFP) or
very low levels of His–HA–CAD. The expressed CAD
was immunoprecipitated from lysates using anti-HA anti-
body. These immunoprecipitates reproducibly contained
Topo IIα, which was not seen in immunoprecipitates of
the much more highly expressed control protein, His–
HA–GFP (Figure 3b). This shows that CAD can interact
with Topo IIα in cell extracts. It is not surprising that only
a fraction of Topo IIα was bound to CAD, as Topo IIα is
abundant in MSB-1 cells, and is presumably present in
vast excess over CAD.
The interaction between Topo IIα and CAD appears to
be functionally significant. In a quantitative assay for
DNA decatenation, purified GST–CAD, either on its own
or as a complex with His–ICAD-L, stimulated the decate-
nation activity of Topo IIα two to threefold, whereas
buffer, GST or GST–ICAD-L had no effect (Figure 3c).
Under these conditions CAD is enzymatically inactive,
and does not interfere with the Topo II assay (which mea-
sures the release of intact minicircles from kinetoplast
networks, see Supplementary material). In other experi-
ments, we could not detect an effect of Topo IIα inhibi-
tion or addition on CAD activity against nuclear chromatin
(Figure 2e, and data not shown).
It is widely accepted that Topo IIα is nuclear [9], and that
CAD must be nuclear during apoptotic execution [4]. The
localization of CAD in non-apoptotic cells has, however,
been more controversial. DFF [3], and then CAD/ICAD
[4] were first identified in cytoplasmic extracts. The first
evidence that the CAD/ICAD complex might be nuclear
was the observation that exogenous ICAD expressed in a
variety of cell types was nuclear [6,8]. Also, our subcellular
fractionation experiments confirmed that endogenous
ICAD is predominantly nuclear [6]. Consistent with this,
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Figure 1
Topo IIα is required for apoptotic chromatin condensation in the
absence of caspase activity. Isolated HeLa cell nuclei were
preincubated with (a–c) diluent alone or with (d) 50 µg/ml ICRF-159,
(e) 50 µg/ml ICRF-187 or (f) 100 µM etoposide (VP16). The nuclei
were then added to (a) buffer or (b–f) apoptotic E/X extract [6] and
incubated for 2 h at 37°C. (d–f) Inhibition of Topo IIα alone only partly
inhibited apoptotic chromatin condensation. (d′–f′) Inhibition of Topo IIα
plus caspases (with 100 µM DEVD–fmk) abolished chromatin
condensation. (d′′–f′′) This block was reversed if 1 µg (2.9 pM) purified
human Topo IIα was added at the start of the 37°C incubation.
(g) Inhibition of CAD with 160 ng of the uncleavable mutant
DM-ICAD-L does not block apoptotic chromatin condensation.
(h) Simultaneous inhibition of CAD plus caspases blocks morphological
apoptosis. (i) Added Topo IIα (1.5 µg) rescues apoptotic morphology
after inhibition of CAD plus caspases. The percentage of apoptotic
cells scored in the microscope is indicated below each micrograph. 
we have identified an autonomous nuclear localization
sequence at the carboxyl terminus of ICAD-L [12]. Here
we address the localization of the CAD nuclease itself.
GFP–CAD is exclusively nuclear when expressed at low
to moderate levels in cultured cells (Figure 4a, panel 2;
see also [12]), and is distributed throughout the nucleus in
a micropunctate pattern that largely follows the DNA dis-
tribution. Endogenous Topo IIα is similarly distributed in
interphase cell nuclei (Figure 4a, panel 3), and in a
merged image (Figure 4a, panel 4), the CAD and Topo
IIα signals superimpose as a yellow signal distributed
throughout the nucleus. To confirm the nuclear localiza-
tion of endogenous CAD, we used a rabbit antiserum to
cloned murine CAD in subcellular fractionation experi-
ments (Figure 4b). A substantial portion of the CAD is
revealed in the nuclear fraction. Although it is possible
that some CAD is normally resident in the cytoplasm, our
results show that much of this protein is nuclear, and
would therefore be available to interact with Topo IIα.
Our results are consistent with models in which CAD and
Topo IIα act in independent pathways in E/X extracts, but
both are modulated by caspases. Several other proteins
that appear to induce apoptotic chromatin condensation in
nuclei have been identified. These include the mitochon-
drial flavoprotein AIF (apoptosis-inducing factor) [13],
L-DNase II [14] and Acinus [15]. The experiments
reported here suggest that, in the absence of caspases,
none of these activities is sufficient to induce apoptotic
chromatin condensation unless either CAD or Topo IIα is
also present and functional.
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Figure 2
Control experiments for the involvement of Topo IIα in apoptotic
chromatin condensation. (a) Purified human Topo IIα (1 µg is 2.9 pM) did
not induce chromatin condensation in nuclei in buffer. (b) Purified human
Topo IIα immunoadsorbed with the anti-Topo IIα antibody Ki-S1 does not
reverse the block to apoptotic chromatin condensation imposed by
simultaneous inhibition of Topo IIα and caspases. (c) Inhibition of
caspases and Topo I (with 10 µM camptothecin (CPT)) had no effect on
apoptotic chromatin condensation beyond that seen when caspases
alone were inhibited. (d) Protein purity was verified by SDS–PAGE of the
Topo IIα preparation in a 10% gel and silver stained. (e) Inhibition of
Topo IIα plus caspases did not affect the digestion of chromosomal DNA
by CAD. Nuclei (5 × 105 per loading) were incubated for 2 h in (1) buffer,
(2) E/X extract, (3) E/X extract plus DEVD–fmk plus ICRF-159, (4) ICRF-
187, or (5) etoposide. Nuclear DNA was isolated and electrophoresed in
a 1% gel containing 0.5 mg/ml ethidium bromide.
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Functional interaction between Topo IIα and CAD in vivo and in vitro.
(a) Human Topo IIα binds in vitro to GST–CAD, but not to GST,
GST–ICAD-L, GST–cBubR1 or GST–hAIRK2. PARP tested as a
control does not bind (see Supplementary material). The Coomassie
Blue-stained gel shows the relative amount of each protein on the
beads. (b) A subfraction of endogenous Topo IIα associates with
tagged CAD in vivo. HA-tagged proteins were immunoprecipitated from
stable transfectants expressing His–HA–CAD or His–HA–GFP and
subjected to SDS–PAGE. Left, blot with anti-Topo IIα showing the input
and unbound fractions (equivalent to 8 × 105 cells), and the fractions
bound to the beads (5 × 106 cells for His–HA–CAD and 1 × 106 cells
for His–HA–GFP). Right, blot with anti-HA showing the input and
unbound fractions (equivalent to 8 × 105 cells for His–HA–CAD and
1.6 × 105 cells for His–HA–GFP). We estimate that His–HA–GFP is
expressed roughly 25–100-fold more abundantly than His–HA–CAD in
these cells. (c) GST–CAD stimulates Topo IIα activity measured using a
kinetoplast minicircle decatenation assay (see Supplementary material).
The error bars represent SEM for two independent assays.
Although a role for Topo IIα in apoptotic execution has
been controversial [16,17], its involvement in generating
high-molecular-weight DNA fragments following oxida-
tive stress has recently been demonstrated [18]. In addi-
tion, Topo IIα has been shown to stimulate the activity of
CAD against a naked DNA substrate approximately eight-
fold, although the cleavage of chromatin was essentially
unaffected [19]. The direct interaction between Topo IIα
and CAD we show here might result in targeting of CAD
to sites occupied by Topo IIα at the base of chromosomal
loop domains. At those sites, CAD might initially stimu-
late Topo IIα activity and then subsequently, upon cleav-
age of ICAD-L by caspases, it might commence the
wholesale digestion of DNA characteristic of apoptosis,
possibly being further stimulated by interactions with
Topo IIα. Our  results predict that CAD cleavage might
initiate at or near Topo IIα-binding sites.
Supplementary material
Supplementary material, including a full description of the methods with
references, is available at http://current-biology.com/supmat/sup-
matin.htm.
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Figure 4
(a) Topo IIα and GFP–CAD co-localize in healthy cell nuclei. Chicken
DU249 cells were transfected with constructs expressing GFP–CAD
and stained for endogenous Topo IIα. The two proteins were
distributed in the nucleus in an overlapping micropunctate pattern.
A single deconvolved optical section is shown. The scale bar
represents 5 µm. (b) A significant portion of endogenous CAD is
nuclear. HeLa S3 cells were fractionated into nucleus and cytoplasm
[6] and immunoblotted with rabbit anti-mouse CAD, mouse anti-
tubulin, and human autoantibody against Topo I.
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Supplementary materials and methods
Preparation of apoptotic extracts and in vitro apoptosis
reaction
Apoptotic (E/X) extracts [S1] were prepared from chicken DU249 cells
treated for 12 h with 0.5 µM staurosporine (Sigma). Cells were washed
in KPM buffer (50 mM PIPES-KOH pH 7.0, 50 mM KCl, 10 mM EGTA,
2 mM MgCl2, 20 mM cytochalasin B (Sigma), 1 mM DTT, 0.1 mM
PMSF, 1 µg/ml each of chymostatin, leupeptin, antipain, pepstatin A)
[S2], subjected to several cycles of freezing and thawing and further
disrupted by mild sonication. The cell lysate was then centrifuged at
139,000g for 2 h, yielding clear cytosolic extracts with a protein con-
centration of 20–30 mg/ml (measured by the Bradford assay [3]).
HeLa nuclei (106 per incubation) were preincubated for 30 min at 37°C
with either the Topo IIα inhibitors ICRF-159, ICRF-187 (50 µg/ml, both
gifts of A. Imondi, Pharmacia) or etoposide (VP-16, 100 µM, Sigma), or
the Topo I inhibitor camptothecin (0.1, 1 or 10 µM, Calbiochem), or
diluent. For CAD inhibition, E/X extracts were preincubated with ICAD-L
or CAD buffer (10 mM HEPES pH 7.4, 50 mM NaCl, 5 mM EGTA,
2 mM MgCl2, 1 mM DTT) for 15 min at 37°C. For caspase inhibition,
E/X extracts were preincubated with DEVD–fmk (100 µM, Calbiochem)
or diluent for 15 min at 37°C. Nuclei were then added (up to 106 nuclei
per 20 µl of extract) and incubated at 37°C for up to 6 h in the presence
of an ATP regeneration system [S2]. In certain experiments, 1 or 1.5 µg
of purified human Topo IIα expressed in Saccharomyces cerevisiae
[S4,S5] was added to the incubation. This corresponds to 2.9 pmol
dimer, a ~3× physiological level of 1.7 × 106 molecules per nucleus
[S6]. Nuclei were subsequently stained with DAPI to observe chromatin
condensation, solubilized in SDS–sample buffer for protein analysis, or
lysed for analysis of DNA ladder formation.
Construction of clones
For construction of intein–ICAD, mouse full-length ICAD-L [S7] (gift of S.
Nagata, Osaka) was cloned into the NcoI/SmaI cloning sites of pTYB4
(New England BioLabs Inc.). GST–CAD was prepared by cloning full-
length murine CAD into the pGEX 4T-1 (Pharmacia Biotech) EcoRI and
XhoI cloning site. To make the plasmid encoding the GST–CAD His6-
tagged ICAD combination (GST–CAD/His–ICAD), His–ICAD in
pRSETB [S1] was obtained by PCR with primer (5′-TGAGACGTC-
TAATACGACTCAC-3′) and primer (5′-GTCGACGTCAGCAAAAAAC-
CCC-3′) and cloned into the AatII site of pGEX 4T-1 containing GST–CAD.
To make the Zeo–His–HA vector, first a His tag was constructed by
ligation of oligonucleotides (5′-CTAGCATGCATCATCATCATCATCAC-
CGCGGA-3′) and (5′-AGCTTCCGCGGTGATGATGATGATGATG-
CATG-3′). The resulting fragment was ligated into vector pZeoSV2+
(Invitrogen) that had been digested with NheI and HindIII. The HA tag in
Supplementary material
Figure S1
The kinetoplast minicircle decatenation assay.
(a) Experiment. All samples contained: 5 nM
kinetoplast-DNA, 1 mM ATP and 10 nM
Topo II (except where indicated) in 50 mM
Tris pH 7.9, 100 mM KCl, 10 mM MgCl2,
0.5 mM NaEDTA pH 8.0, 2.5% glycerol. The
positions of the kinetoplast network
(substrate), released minicircles (Topo II
reaction product) and linear DNA (product of
cleavage by CAD) are indicated. Less than
3% of the kinetoplast DNA minicircles are
cleaved. Because decatenation is determined
by quantifying released DNA minicircles (and
not by disappearance of the kinetoplast DNA
substrate), any CAD-mediated DNA cleavage
would deplete the Topo II decatenation
substrate and thus decrease (not increase)
observed levels of decatenation. (b) Controls.
This experiment is the same as in (a), except
that Topo II was omitted from all GST,
GST–CAD, GST–CAD/His–ICAD, and
GST–ICAD samples. That is, the only sample
that contained Topo II is that labelled Topo II.
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pBluescript KS (Stratagene) was digested with SacII and blunt-ended
with T4 DNA polymerase plus 100 µM dNTPs, and digested with EcoR I.
The resulting fragment was ligated into vector pZeo–His that had been
digested with KpnI and blunt-ended with T4 DNA polymerase plus
100 µM dNTPs, and digested with EcoR I. To make Zeo–His–HA–CAD
and Zeo–His–HA–GFP, the CAD ORF was obtained by PCR from a
plasmid containing the full-length CAD cDNA (gift of S. Nagata), cloned
into pBluescript KS (Stratagene) and digested with EcoRI and XhoI. GFP
was obtained by PCR using primer T7 and primer (5′-CCGCTCGAGT-
TACTTGTACAGC-3′) from an enhanced GFP–lamin A in pCDNA 3 (gift
of Larry M. Karnitz, Mayo Research Foundation), then digested with
EcoRI and XhoI. The resulting fragments were ligated into vector
Zeo–His–HA that had been digested with EcoRI and XhoI.
Expression and purification of GST–ICAD, GST–CAD,
GST–CAD/His–ICAD and GST
Plasmids encoding the glutathione-S-transferase (GST) fusion proteins
GST–ICAD, GST–CAD, GST–CAD/His–ICAD, GST–BubR1, GST–hAIRK2
and GST alone transformed into E. coli BL21(DE3)Lys S cells were
grown to OD600 = 0.5–0.7, and protein expression was induced with
isopropylthiogalactoside (IPTG; 0.3–0.5 mM) for 3–5 h. Cells were col-
lected by centrifugation at 5000g for 10 min and frozen at –80°C. 
GST–CAD/His–ICAD was first purified with 0.5 ml Ni–agarose (Qiagen)
as described previously for the purification of His6–ICAD purification
[S1]. Protein eluted from the column was diluted 20-fold into GST wash
buffer (PBS, 5 mM EDTA, 5 mM DTT, 1% Triton X-100), and then puri-
fied a second time over glutathione–sepharose as described below.
Pellets of E. coli expressing GST–ICAD, GST–CAD or GST were
thawed on ice and resuspended in lysis buffer (PBS, 5 mM EDTA,
5 mM DTT) with lysozyme (final concentration 1 mg/ml) and incubated
on ice for 30 min. After sonication, Triton X-100 was added to 1% and
the lysate was centrifuged at 4000g for 20 min. The supernatant was
mixed with glutathione–sepharose 4B (Pharmacia Biotech) which had
been equilibrated with PBS and incubated on a rotating mixer for 1 h at
4°C. The sepharose beads were washed in batch three times with
wash buffer. GST–ICAD and GST were eluted with elution buffer 1
(10 mM glutathione, 50 mM Tris-HCl pH 8.0). GST–CAD, and
GST–CAD/His–ICAD were eluted with elution buffer 2 (20 mM glu-
tathione, 100 mM Tris-HCl pH 8.0, 120 mM NaCl). The eluted proteins
were dialysed for at least 3 h against two changes of CAD buffer
(10 mM HEPES pH 7.4, 50 mM NaCl, 5 mM EGTA, 2 mM MgCl2,
1 mM DTT), aliquoted, and frozen in liquid nitrogen.
Expression and purification of intein–ICAD
Intein–ICAD encoded by pTYB4/ICAD-L was expressed in E. coli
ER2566 and purified using the IMPACTTM T7 system (New England
BioLabs Inc.) following the manufacturer’s instructions. Intein–ICAD
bound to chitin beads was left at 4°C overnight in cleavage buffer
(20 mM Tris-HCl pH 8.0, 50 mM NaCl, 0.1 mM EDTA, 30 mM DTT).
The protein was eluted with cleavage buffer without DTT. The eluted
protein was dialysed for at least 3 h against two changes of CAD buffer
(10 mM HEPES pH 7.4, 50 mM NaCl, 5 mM EGTA, 2 mM MgCl2,
1 mM DTT) aliquoted and frozen in liquid nitrogen.
Binding of Topo IIα to GST fusion proteins in vitro
Purified Topo IIα (125 ng) and 53.3 ng purified PARP (in PBS + 5 mM
DTT, 10 mM EDTA, 1% Triton X-100) was incubated with glutathione–
sepharose beads either alone, or with bound GST, GST–ICAD-L,
GST–CAD, GST–cBubR1 or GST–hAIRK2. The bound fraction was
resolved by SDS–PAGE (10% gel), and Topo IIα was detected by
immunoblotting with monoclonal antibody Ki-S1. PARP was detected
by immunoblotting with monoclonal antibody C2-10. 
Immunoprecipitation of HA-tagged CAD and GFP from stable
cell lines
Stable lines of MSB-1 chicken lymphoblastoid cells expressing His–
HA–CAD and His–HA–GFP were obtained by electroporation with
Zeo–His–HA–CAD and Zeo–His–HA–GFP (310 V 975 µF (BioRad
Gene-Pulser with 0.4 mm cuvettes), selected with 400 µg/ml Zeosin
(Invitrogen) and confirmed by immunoblotting with anti-HA tag anti-
body. For immunoprecipitation, cells were harvested, washed twice
with PBS/EDTA and lysed by sonication in IPP150 (10 mM Tris
pH 8.0, 150 mM NaCl, 0.1% NP-40), and insoluble material removed
by centrifugation for 5 min at 8161g at 4°C. HA-conjugated proteins
were immunoadsorbed using monoclonal antibody 12CA5 preloaded
onto Affi-Prep Protein A Support beads (BioRad). After incubation for
1 h at 4°C the beads were washed three times for 5 min with 25 bed
volumes of either IPP150, IPP200 (200 mM NaCl) or IPP300 (300 mM
NaCl). Bound proteins were subjected to SDS–PAGE in 10%
Prosieve 50 Acrylamide gels (FMC), transferred to Hybond C nitrocel-
lulose (Amersham ), and detected by enhanced chemiluminescence.
Topo IIα was detected with Rabbit G [S8] diluted 1:1000. HA–CAD
was detected with mouse monoclonal 12CA5 diluted 1:1000.
Kinetoplast minicircle decatenation assay
Kinetoplast DNA (0.3 µg) was incubated with 10 nM purified human
Topo IIα plus 10 nM GST–CAD, GST–ICAD, GST–CAD + GST–ICAD,
or GST alone for 10 min at 37°C [S9]. The reaction was stopped by
addition of DNA loading buffer, heated at 65°C for 10 min, loaded onto
a 1% agarose gel containing 0.5 mg/ml ethidium bromide and run at 90
V for 2 h (Figure S1), and the minicircles released by decatenation were
quantified. No detectable intact minicircles were released in incubations
with GST–CAD or GST–CAD + His–ICAD-L in the absence of Topo
IIα. Under these conditions, the GST–CAD is catalytically inactive and
does not interfere with the assay.
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